Long‑responders to anti‑HER2 therapies: A case report and review of the literature

Cantini,Luca; Pistelli,Mirco; Savini,Agnese; Bastianelli,Lucia; Della Mora,Arianna; Merloni,Filippo; Burattini,Michela; Berardi,Rossana

doi:10.3892/mco.2017.1495

Long‑responders to anti‑HER2 therapies: A case report and review of the literature

Authors:
- Luca Cantini
- Mirco Pistelli
- Agnese Savini
- Lucia Bastianelli
- Arianna Della Mora
- Filippo Merloni
- Michela Burattini
- Rossana Berardi
View Affiliations

Affiliations: Medical Oncology, Marche Polytechnic University, University Hospital Ospedali Riuniti Ancona, I-60126 Ancona, Italy
Published online on: November 8, 2017 https://doi.org/10.3892/mco.2017.1495
Pages: 147-152

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Since the introduction of targeted therapies, prognosis in human epidermal growth factor receptor (HER) 2‑positive metastatic breast cancer (MBC) has radically changed. The addition of Pertuzumab to Trastuzumab and standard chemotherapy has further increased patients' overall survival (OS). However, there is no agreement regarding the optimal duration of trastuzumab therapy in selected patients achieving long‑term complete remission. In addition, no potential factors of long‑term benefit have been identified yet. In the present study, we report the case of a MBC woman who was successfully treated with trastuzumab for over 10 years. At the time of diagnosis (February 2005), she revealed lung, nodal and bone metastases. Therefore, a first‑line chemotherapy with Epirubicine and Docetaxel was administered for 6 cycles and then the patient started Trastuzumab plus hormonal therapy until reaching a sensible reduction of mammary lump and disappearance of distant metastases. Following a multidisciplinary evaluation, in November 2006, the patient underwent radical mastectomy and axillary dissection, achieving a complete remission. She continued Trastuzumab until September 2015 (for a total of 156 cycles) when a pleural diffusion was demonstrated. Long‑term survival during anti‑HER2 treatment remains a rare and optimal situation. Currently, no data exist to support trastuzumab interruption in this setting and collaborative efforts to better analyze the characteristics of long‑responder patients are needed. Data regarding prognostic factors in this setting are relatively confusing. Our review reveals that hormonal receptor (HR)-positive disease is associated with a better prognosis, whereas the role of visceral spread differs by single or dual target anti HER2-inhibition. The introduction of Pertuzumab is raising concerns in terms of toxicity and its cost effectiveness. While waiting for novel molecular data and randomized trials, available evidence advocates continuous use of anti‑HER2 therapies until disease progression or development of side effects.

View Figures

View References

1	Del Mastro L, Lambertini M, Bighin C, Levaggi A, D'Alonzo A, Giraudi S and Pronzato P: Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients. Expert Rev Anticancer Ther. 12:1391–1405. 2012. View Article : Google Scholar : PubMed/NCBI
2	Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 344:783–792. 2001. View Article : Google Scholar : PubMed/NCBI
3	Swain SM, Kim SB, Cortés J, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Knott A, et al: Overall survival benefit with pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer in CLEOPATRA, a randomised Phase 3 study. Lancet Oncol. 14:461–471. 2013. View Article : Google Scholar : PubMed/NCBI
4	Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, et al: Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 366:109–119. 2012. View Article : Google Scholar : PubMed/NCBI
5	Lobbezoo DJ, van Kampen RJ, Voogd AC, Dercksen MW, van den Berkmortel F, Smilde TJ, van de Wouw AJ, Peters FP, van Riel JM, Peters NA, et al: Prognosis of metastatic breast cancer subtypes: The hormone receptor/HER2-positive subtype is associated with the most favorable outcome. Breast Cancer Res Treat. 141:507–514. 2013. View Article : Google Scholar : PubMed/NCBI
6	Swain SM, Kim SB, Cortés J, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Knott A, et al: Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): Overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 14:461–471. 2013. View Article : Google Scholar : PubMed/NCBI
7	Maciá Escalante S, Rodríguez Lescure A, Sanz V Pons, Martínez Banaclocha N, Guillén Ponce C and Mena A Carrato: A patient with breast cancer with hepatic metastases and a complete response to herceptin as monotherapy. Clin Transl Oncol. 8:761–763. 2006. View Article : Google Scholar : PubMed/NCBI
8	Beda M, Basso U, Ghiotto C and Monfardini S: When should trastuzumab be stopped after achieving complete response in HER2-positive metastatic breast cancer patients? Tumori. 93:491–492. 2007.PubMed/NCBI
9	Badulescu F, Badulescu A, Paul D, Popescu CF and Florescu C: More than 9 years of continuous trastuzumab treatment in metastatic breast cancer without cardiac toxicity: A case report and literature review. Onco Targets Ther. 7:1911–1917. 2014.PubMed/NCBI
10	Artac M, Koral L, Toy H, Guler T, Boruban MC and Altundag K: Complete response and long-term remission to anti-HER2 combined therapy in a patient with breast cancer presented with bone marrow metastases. J Oncol Pharm Pract. 20:141–145. 2014. View Article : Google Scholar : PubMed/NCBI
11	Ihnenfeld A, rciénega I, Imesch P, Fink D and Dedes KJ: Prolonged complete remission of metastatic HER2-positive breast cancer after continuous trastuzumab treatment: A case report and review of the literature. Target Oncol. 10:297–301. 2015. View Article : Google Scholar : PubMed/NCBI
12	Syrios J, Dokou A and Tsavaris N: Sustained complete remission of human epidermal growth factor receptor 2-positive metastatic breast cancer in the liver during long-term trastuzumab (Herceptin) maintenance therapy in a woman: A case report. J Med Case Rep. 4:4012010. View Article : Google Scholar : PubMed/NCBI
13	Hsieh A, Pittman K, Patterson WK and Townsend A: Can maintenance trastuzumab be stopped in patients with HER2-positive metastatic breast cancer? BMJ Case Rep 2015. pii:bcr2014207750. 2015.
14	Cardoso F, Harbeck N, Fallowfield L, Kyriakides S and Senkus E; ESMO Guidelines Working Group, : Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 23 Suppl 7:vii11–vii19. 2012. View Article : Google Scholar : PubMed/NCBI
15	Giordano SH, Temin S, Kirshner JJ, Chandarlapaty S, Crews JR, Davidson NE, Esteva FJ, Gonzalez-Angulo AM, Krop I, Levinson J, et al: Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American society of clinical oncology clinical practice guideline. J Clin Oncol. 32:2078–2099. 2014. View Article : Google Scholar : PubMed/NCBI
16	Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, et al: III ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3). Ann Oncol. Feb 19–2017.(Epub ahead of print). View Article : Google Scholar
17	Yeo B, Kotsori K, Mohammed K, Walsh G and Smith IE: Long-term outcome of HER2 positive metastatic breast cancer patients treated with first-line trastuzumab. Breast. 24:751–757. 2015. View Article : Google Scholar : PubMed/NCBI
18	Witzel I, Müller V, Abenhardt W, Kaufmann M, Schoenegg W, Schneeweis A and Jänicke F: Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer-results from the HER-OS patient registry. BMC Cancer. 14:8062014. View Article : Google Scholar : PubMed/NCBI
19	Luen SJ, Salgado R, Fox S, Savas P, Eng-Wong J, Clark E, Kiermaier A, Swain SM, Baselga J, Michiels S and Loi S: Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: A retrospective analysis of the CLEOPATRA study. Lancet Oncol. 18:52–62. 2017. View Article : Google Scholar : PubMed/NCBI
20	Yardley DA, Tripathy D, Brufsky AM, Rugo HS, Kaufman PA, Mayer M, Magidson J, Yoo B, Quah C and Yood M Ulcickas: Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER. Br J Cancer. 110:2756–2764. 2014. View Article : Google Scholar : PubMed/NCBI
21	Harano K, Lei X, Gonzalez-Angulo AM, Murthy RK, Valero V, Mittendorf EA, Ueno NT, Hortobagyi GN and Chavez-MacGregor M: Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 159:367–374. 2016. View Article : Google Scholar : PubMed/NCBI
22	Fiteni F, Villanueva C, Bazan F, Perrin S, Chaigneau L, Dobi E, Montcuquet P, Cals L, Meneveau N, Nerich V, et al: Long-term follow-up of patients with metastatic breast cancer treated by trastuzumab: Impact of institutions. Breast. 23:165–169. 2014. View Article : Google Scholar : PubMed/NCBI
23	Murthy P, Kidwell KM, Schott AF, Merajver SD, Griggs JJ, Smerage JD, Van Poznak CH, Wicha MS, Hayes DF and Henry NL: Clinical predictors of long-term survival in HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 155:589–595. 2016. View Article : Google Scholar : PubMed/NCBI
24	Gullo G, Zuradelli M, Sclafani F, Santoro A and Crown J: Durable complete response following chemotherapy and trastuzumab for metastatic HER2-positive breast cancer. Ann Oncol. 23:2204–2205. 2012. View Article : Google Scholar : PubMed/NCBI
25	Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Heeson S, et al: Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 372:724–734. 2015. View Article : Google Scholar : PubMed/NCBI